Market Access Multiple myeloma drug Blenrep backed for wider NHS use PharmaphorumThe revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.Market AccessOncologyRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely. Market AccessOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Daiichi Sankyo and Interna partner for MNM-targeted delivery solutionsNext: Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA Related Stories Market Access NICE aims to cut funding for Amgen lung cancer drug Lumykras pharminent July 9, 2026 Market Access UK, pharma industry pilot rapid access routes for medicines pharminent July 5, 2026 Market Access Medicare GLP-1 Bridge Launches July 1 With $50 Copays pharminent July 3, 2026
